Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guess, $3 by June, then depending on trial results, much higher!
$BPSR MONSTA!!!!
BREAKOUT!!!!
Could happen this summer IMHO once drug is approved for emergency purposes in India or the fall when FDA trials are completed.
Here we GO!!!!! BPSR blasting out of of orbit!
T-Trade already at 44 cents!
Folks, BP*SR went up 636% today based on news of a successful Covid treatment trial results on 20 patients today. I believe a similar spike will happen to TBPMF with costive results for Tetra Bio Pharma's drug trial.
Keep adding!
TBPMF = Life Changer!
It's true. Very strange it hasn't caught iHubers' attention. Didn't make it on the Most Posted boards. We can fix that tomorrow, though. Lol
BPSR could be a life changer!
Mega news today. Successful Covid treatment trial on 20 patients, with upcoming 63 patient trial to be completed by June. Huge catalysts.
I added myself a moderator and added to the Intro ion this board. Let me know if anyone would like to add anything else. We have a multiple dollar runner here IMHO. Do your own DD and GLTA!
$BPSR
BPSR >>> QNTA
It broke its resistance so I doubt this will go back down. Should GAP up tomorrow IMO. Perhaps a big correction later in the week might get it down, but again, I doubt it will go much lower than 25 cents.
Agreed, but this is well beyond retail buying now. iHub-ers are small fish in BPSR pond Lol.
$BPSR Dollars here!
BPSR UP 633% EOD!!! Organicell Announces Positive Results of Initial COVID-19 Zofin™ Patient Trial in India and Trial Expansion
STILL CHEAP - MULTIPLE DOLLAR RUNNER IMHO
Published: Apr 28, 2021
https://www.biospace.com/article/releases/organicell-announces-positive-results-of-initial-covid-19-zofin-patient-trial-in-india-and-trial-expansion
MIAMI--(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients.
The initial ten trial participants were hospitalized patients and were treated at Narayana Hrudayalaya Hospital in Bangalore, Lisa Hospital in Kozhikode, Kerala and Prime Indian Hospital in Chennai, and all patients have recovered from their symptoms and have since been discharged from the hospital. Based on the initial results of this trial, the trial will be expanded to an additional sixty-five patients with moderate to severe COVID-19, who will be treated at these hospitals over the next several weeks, with treatments expected to be completed by the end of June 2021.
If the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin™ in India as a therapeutic for treating COVID-19.
The Indian Health Ministry is reporting more than 350,000 new COVID infections and over 2,500 deaths per day, a world record, and India is now seeing more new infections than any other country, almost half of all new cases in a global surge.
“The explosive spread of COVID-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic. We are hopeful that Zofin™ can continue to help these patients, and we will do everything we can to expedite this process,” said Albert Mitrani, CEO of Organicell.
“We are very encouraged with the results shown by patients using Zofin™ and are hopeful that the remaining trial patients will show similar results. These trials could set the stage for a very quick Emergency Use Approval to be able to use Zofin™ for all of our patients,” said Doctor Matthew Roshan of CWI India.
About Zofin™:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005214/en/
Contacts
Jeffrey Freedman
RooneyPartners
646-432-0191
jfreedman@rooneyco.com
Source: Organicell Regenerative Medicine, Inc.
Powered by Business Wire
View this news release online at:
http://www.businesswire.com/news/home/20210428005214/en
Multiple dollars here!
HOD Breakout mode!!! Should gap up tomorrow IMO
Very sharp looking!
The Float is higher than 15M. Float hasn't been updated. 194M Unrestricted Shares was updated this month, so much closer to reality.
Unrestricted
194,129,465
04/09/2021
Still a reasonably small float.
Small Float
Authorized Shares
2,500,000,000
04/09/2021
Outstanding Shares
1,041,341,874
04/09/2021
Restricted
847,212,409
04/09/2021
Unrestricted
194,129,465
04/09/2021
Agreed. This is why I'm now.
Looks like next very big catalyst will be in June.
"Based on the initial results of this trial, the trial will be expanded to an additional sixty-five patients with moderate to severe COVID-19, who will be treated at these hospitals over the next several weeks, with treatments expected to be completed by the end of June 2021.
If the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin™ in India as a therapeutic for treating COVID-19."
I don't see how it can't go higher, if it reached 45 cents on lesser news in February.
BPSR UP 490%!!! Organicell Announces Positive Results of Initial COVID-19 Zofin™ Patient Trial in India and Trial Expansion
Published: Apr 28, 2021
https://www.biospace.com/article/releases/organicell-announces-positive-results-of-initial-covid-19-zofin-patient-trial-in-india-and-trial-expansion
MIAMI--(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients.
The initial ten trial participants were hospitalized patients and were treated at Narayana Hrudayalaya Hospital in Bangalore, Lisa Hospital in Kozhikode, Kerala and Prime Indian Hospital in Chennai, and all patients have recovered from their symptoms and have since been discharged from the hospital. Based on the initial results of this trial, the trial will be expanded to an additional sixty-five patients with moderate to severe COVID-19, who will be treated at these hospitals over the next several weeks, with treatments expected to be completed by the end of June 2021.
If the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin™ in India as a therapeutic for treating COVID-19.
The Indian Health Ministry is reporting more than 350,000 new COVID infections and over 2,500 deaths per day, a world record, and India is now seeing more new infections than any other country, almost half of all new cases in a global surge.
“The explosive spread of COVID-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic. We are hopeful that Zofin™ can continue to help these patients, and we will do everything we can to expedite this process,” said Albert Mitrani, CEO of Organicell.
“We are very encouraged with the results shown by patients using Zofin™ and are hopeful that the remaining trial patients will show similar results. These trials could set the stage for a very quick Emergency Use Approval to be able to use Zofin™ for all of our patients,” said Doctor Matthew Roshan of CWI India.
About Zofin™:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005214/en/
Contacts
Jeffrey Freedman
RooneyPartners
646-432-0191
jfreedman@rooneyco.com
Source: Organicell Regenerative Medicine, Inc.
Powered by Business Wire
View this news release online at:
http://www.businesswire.com/news/home/20210428005214/en
BPSR UP 490%!!! Organicell Announces Positive Results of Initial COVID-19 Zofin™ Patient Trial in India and Trial Expansion
Published: Apr 28, 2021
https://www.biospace.com/article/releases/organicell-announces-positive-results-of-initial-covid-19-zofin-patient-trial-in-india-and-trial-expansion
MIAMI--(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients.
The initial ten trial participants were hospitalized patients and were treated at Narayana Hrudayalaya Hospital in Bangalore, Lisa Hospital in Kozhikode, Kerala and Prime Indian Hospital in Chennai, and all patients have recovered from their symptoms and have since been discharged from the hospital. Based on the initial results of this trial, the trial will be expanded to an additional sixty-five patients with moderate to severe COVID-19, who will be treated at these hospitals over the next several weeks, with treatments expected to be completed by the end of June 2021.
If the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin™ in India as a therapeutic for treating COVID-19.
The Indian Health Ministry is reporting more than 350,000 new COVID infections and over 2,500 deaths per day, a world record, and India is now seeing more new infections than any other country, almost half of all new cases in a global surge.
“The explosive spread of COVID-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic. We are hopeful that Zofin™ can continue to help these patients, and we will do everything we can to expedite this process,” said Albert Mitrani, CEO of Organicell.
“We are very encouraged with the results shown by patients using Zofin™ and are hopeful that the remaining trial patients will show similar results. These trials could set the stage for a very quick Emergency Use Approval to be able to use Zofin™ for all of our patients,” said Doctor Matthew Roshan of CWI India.
About Zofin™:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005214/en/
Contacts
Jeffrey Freedman
RooneyPartners
646-432-0191
jfreedman@rooneyco.com
Source: Organicell Regenerative Medicine, Inc.
Powered by Business Wire
View this news release online at:
http://www.businesswire.com/news/home/20210428005214/en
Organicell Announces Positive Results of Initial COVID-19 Zofin™ Patient Trial in India and Trial Expansion
Published: Apr 28, 2021
Logo
April 28, 2021 11:30 UTC
MIAMI--(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients.
The initial ten trial participants were hospitalized patients and were treated at Narayana Hrudayalaya Hospital in Bangalore, Lisa Hospital in Kozhikode, Kerala and Prime Indian Hospital in Chennai, and all patients have recovered from their symptoms and have since been discharged from the hospital. Based on the initial results of this trial, the trial will be expanded to an additional sixty-five patients with moderate to severe COVID-19, who will be treated at these hospitals over the next several weeks, with treatments expected to be completed by the end of June 2021.
If the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin™ in India as a therapeutic for treating COVID-19.
The Indian Health Ministry is reporting more than 350,000 new COVID infections and over 2,500 deaths per day, a world record, and India is now seeing more new infections than any other country, almost half of all new cases in a global surge.
“The explosive spread of COVID-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic. We are hopeful that Zofin™ can continue to help these patients, and we will do everything we can to expedite this process,” said Albert Mitrani, CEO of Organicell.
“We are very encouraged with the results shown by patients using Zofin™ and are hopeful that the remaining trial patients will show similar results. These trials could set the stage for a very quick Emergency Use Approval to be able to use Zofin™ for all of our patients,” said Doctor Matthew Roshan of CWI India.
About Zofin™:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005214/en/
Contacts
Jeffrey Freedman
RooneyPartners
646-432-0191
jfreedman@rooneyco.com
Source: Organicell Regenerative Medicine, Inc.
Powered by Business Wire
View this news release online at:
http://www.businesswire.com/news/home/20210428005214/en
What is the Float here? Congrats everyone!
Watkins is 100% committed with UNSS since Entrex received funding to support the company by UNSS, so no concerns there. Watkins is of the same mindset as AD1251, that the OTC is slow for the reasons he mentioned, but will eventually get there. In the meantime, I'm focussing on what is happening on he business side. So many opportunities!
UNSS Long & Strong
There we will an incredible catalyst within 4 weeks or less, when CEO will likely provide preliminary results from first human inhalation QIXLEEF drug trial, used as a more effective pain killer than morphine (a multi billion dollar industry). Full trial will last 10 weeks.
Excellent summary of our situation, and very educating Lol. Thank you.
CE Approval is a nuisance that needs to be dealt with, but not the reason we are all holding. It will all be worth it! AIMHO.
UNSS Long & Strong
I thought this was already the case since January.
You bet I am. I'm way up, and the potential here is incredible! Entrex have a solid 3-5 year plan to become a multi-billion plus company, and Watkins has been executing towards that goal. This is not a stinky pinky momentum stock Lol.
UNSS LONG & STRONG
They have enough credits to sell for a lifetime and will probably add more Lol
Looks like tweets don't work anymore. I'm out for now.
Filings completed!!!!
33+ cents hitting. Dollarland plus possible soon with huge catalysts in the pipeline!
PPS is in breakout mode!
Great tweet. Word getting out big time!
Great to see
@BIOTECanada
cover
@TetraBioPharma
$TBP as they embark on their ground-breaking trial in the USA to see if #cannabis can be used an alternative in the #opioidcrisis #pharma #science Flag of Canada
https://twitter.com/DianeReardon33/status/1386669957010886660?s=20
"There remains a need for #safe, #effective & non-addictive alternatives to #opioids. This article in @BIOTECanada features Tetra's leadership role in creating #cannabinoid-based drugs in the fight against the #opioidcrisis. Pages 76-77 $TBP $TBPMF
https://bit.ly/3gFrdam"
$UNSS New Tweet! Stay patient folks, things are getting real interesting!!
Entrex finds multiple #parties interested in Roper #Carbon Offsets. $UNSS #entrex #roperisland #roper #offsets #carbonoffsets
https://twitter.com/EntrexInc/status/1386710212057260033?s=20
That's great, thanks for the tweet links!
Lol
Will take a while before EEENF goes viral again